Systemic therapy in operable HER2 positive breast cancer

Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision-Making for Early-Stage,...Подробнее

Systemic Therapies Shown to be Effective in HER2-Positive Breast CancerПодробнее

Optimizing Therapy in HER2+ Disease with Dr. Reshma MahtaniПодробнее

Breast Cancer Symposium | Dr M J Paul MS FRCSПодробнее

How to select treatment for HER2+ breast cancer patients with brain metastasis?Подробнее

New & Supporting Data for Optimizing Therapy in HER2+ Breast Cancer | Dr. Mahtani & Dr. SchwartzbergПодробнее

Facebook Live: HER2-Positive Breast Cancer Treatment Options with Dr. Dragana TomicПодробнее

Updates in Systemic Therapy for Breast Cancer 2/8/23Подробнее

Adjuvant Therapy | 2023 Best of Breast ConferenceПодробнее

Sequencing Treatment Options in HER2 Positive Breast Cancer: 2023 Best of Breast ConferenceПодробнее

TUXEDO-1: trastuzumab deruxtecan for the treatment of HER2-positive breast cancer brain metastasesПодробнее

Treatment Overview: HER2-positive Breast CancerПодробнее

Navigating Shifts in the Treatment Landscape for Metastatic HER2-Positive Breast CancerПодробнее

Dr. Barrio on Treatment Options for HER2+ Breast CancerПодробнее

Optimizing adjuvant treatment in HR+/HER2- early breast cancerПодробнее

Tucatinib Combination Improved Survival in HER2–Positive Breast CancerПодробнее

Optimizing Therapy in HER2+ Disease with Dr. Hope S. RugoПодробнее

Ask the expert: Early-stage HER2-positive breast cancer with Adrienne Waks, MDПодробнее

Implications for Systemic Therapy in Breast CancerПодробнее

Rockhampton Information Forum: Dr Rebecca Moor – The systemic treatment of early breast cancerПодробнее

Optimizing treatment in patients with early-stage HER2-positive breast cancerПодробнее